Agilent TechnologiesFRA:AG8 +1.20%94 Shareholder Yield % is 1.58% as of Apr. 2026, which is 34% below its 10-year median of 2.41. GuruFocus rates FRA:AG8 with a GF Score™ of 94/100 and a GF Value™ of €127.75 (Fairly Valued). The stock has 1 warning sign investors should review. Among 204 Medical Diagnostics & Research companies, Agilent Technologies ranks better than 64.22% on this metric.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return.
As of today, Agilent Technologies's Shareholder Yield % was 1.58%.
Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."
Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.
Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.
Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.
Agilent Technologies Shareholder Yield % Related Terms
Agilent Technologies Shareholder Yield % Historical Data
* Premium members only.
The historical data trend for Agilent Technologies's Shareholder Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:AG8 vs NTRA, WAT, IDXX: Shareholder Yield % Comparison
For the Diagnostics & Research subindustry, Agilent Technologies's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Agilent Technologies Shareholder Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Agilent Technologies's Shareholder Yield % distribution charts can be found below:
* The bar in red indicates where Agilent Technologies's Shareholder Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.
Agilent Technologies (FRA:AG8) has a Shareholder Yield % of 1.58% as of Apr. 2026. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Agilent Technologies and its competitors. This is 34% below median its historical median of 2.41. According to the industry distribution chart, Agilent Technologies ranks #73 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 35.8%.
Is Agilent Technologies' Shareholder Yield % too high?
Agilent Technologies' current Shareholder Yield % of 1.58% is 34% below median its 10-year median of 2.41. Based on the distribution chart, Agilent Technologies ranks #73 out of 204 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Agilent Technologies has a GF Score™ of 94/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Agilent Technologies' Shareholder Yield % compare to NTRA and WAT?
According to the Medical Diagnostics & Research industry distribution chart, Agilent Technologies ranks #73 out of 204 companies for Shareholder Yield %. This puts Agilent Technologies in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Medical Diagnostics & Research company?
A good Shareholder Yield % depends on the Medical Diagnostics & Research industry context. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Agilent Technologies and its competitors. Agilent Technologies's current Shareholder Yield % is 1.58%, which is 34% below median its own 10-year median of 2.41. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Agilent Technologies stock overvalued right now?
Based on GuruFocus' analysis, Agilent Technologies (FRA:AG8) is currently considered Fairly Valued. The stock's GF Value™ is €127.75, compared to a current price of €117.65 — trading 7.9% below its estimated fair value. The current Shareholder Yield % is 1.58%, which is 34% below median its 10-year median of 2.41. Agilent Technologies' overall GF Score™ is 94/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Agilent Technologies (FRA:AG8), the current Shareholder Yield % is 1.58% as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Agilent Technologies (FRA:AG8) Overvalued in 2026?
Based on GuruFocus' analysis, Agilent Technologies stock appears to be undervalued.
The current stock price of €117.65 is trading 7.9% below its estimated GF Value™ of €127.75.
GuruFocus considers Agilent Technologies to be Fairly Valued.
Key valuation signals for FRA:AG8:
Shareholder Yield %: 1.58% (34% below median its 10-year median of 2.41)
GF Value™: €127.75 vs. price of €117.65 (7.9% below fair value)
No single metric tells the full story. See the FRA:AG8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and diagnostics, cross lab operations consisting of consumables and services, and applied end markets. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.
94GF Score
Get the complete analysis for FRA:AG8
Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:AG8 has been successfully added to your 
